Discover EncircleRx, a data-driven portfolio that helps plan sponsors reduce costs and enhance outcomes for cardiodiabesity—cardiovascular disease, diabetes and obesity.
What is Cardiodiabesity?
The connection linking cardiovascular disease, diabetes and obesity
Nearly 42% of the United States is obese.1 Many Americans are doing everything they can to shed extra weight—even if that means using off-label medications which are in short supply for those who desperately need them—but prevalence of obesity remains high. Unaddressed, this challenge often leads to dire and expensive health consequences.
Up to 53% of new type 2 diabetes cases in the U.S. today are linked to obesity, meaning that over half of diabetes cases could be prevented by more effective obesity treatment.2
Of those diagnosed with type 2 diabetes, 85% have high cholesterol and/or high blood pressure, putting them at risk for a third, potentially fatal comorbidity: cardiovascular disease.3
1. CDC, 2021. https://www.cdc.gov/nchs/data/nhsr/nhsr158-508.pdf
2. American Heart Association, 2021. https://www.ahajournals.org/doi/full/10.1161/JAHA.120.018799
3. Express Scripts book of business data, 2016.
Cardiodiabesity affects health care costs as one of the most expensive condition categories to treat.
annual U.S. medical costs for obesity4
4. CDC, 2022, https://www.cdc.gov/chronicdisease/ resources/publications/factsheets/nutrition.html
annual cost of health care services, medications and productivity loss due to heart disease5
5. CDC, 2021, https://www.cdc.gov/policy/polaris/ healthtopics/heartdisease/index.htm
the cost of diagnosed diabetes in one year6
6. CDC, 2021, https://www.cdc.gov/policy/polaris/healthtopics/diabetes/index.htm
Cardiodiabesity is complicated…but its benefits management doesn’t have to be.
Health Plans to Combat Cardiodiabesity
Addressing the complexity of these conditions requires a tailored, data-driven and innovative approach to both decrease pharmacy spend and save lives.
Evernorth’s transparent, proactive and innovative capabilities come together to help plans manage cardiodiabesity, unlocking a benefit that tackles this high-cost and highly prevalent disease category in a more streamlined way.
Cardiodiabesity will be the first solution from the EncircleRx portfolio and will provide optionality to manage trend and improve patient outcomes by disease state.
Our approach targets complex pain points to achieve lower costs and deliver better outcomes for plans and members.
Unlocking client-specific insights
Our performance dashboard can integrate your medical data to assess clinical and financial performance for greater insights.
Unlocking integrated vendor partnerships
New vendor relationships are in development to expand and streamline our diagnostic and intervention capabilities—supporting members in their health journey and providing visibility to support closing gaps in care.
Unlocking savings on pharmacy benefit
We are working to allow optionality at the client level to reduce drug spend while still allowing access for those in need.